Articles related to MOVEMENT DISORDERS

Multiple studies’ pooled data revealed a significantly increased risk of Parkinson’s when combined with bullous pemphigoid, a rare skin condition, inflammatory bowel disease (IBD), or Sjögren’s syndrome. Immune response impairment has been linked to Parkinson’s disease in a growing body of evidence. Indeed, some studies have suggested that the neurodegenerative disease may be exacerbated by autoimmune processes, which occur when the immune system incorrectly attacks and destroys healthy tissue.

Per Svenningsson, MD, PhD, a neurologist with expertise in Parkinson’s disease, will serve as the multicenter trial’s principal investigator. He previously oversaw a clinical study using montelukast (Singulair) tablets to treat PD. The multicenter trial is anticipated to begin between July and September. During the 18-month trial, participants will be randomized to receive either montelukast VersaFilm or a placebo film. IntelGenx plans to use the results to enhance the clinical development of its montelukast VersaFilm for Parkinson’s.

It wasn’t carpal tunnel. It wasn’t just anxiety, and Ed wasn’t having a stroke. Even after a complete neurological assessment, it wasn’t “mild cognitive impairment.” For months, Ed’s life was plagued with psychiatric and movement disorders that puzzled his wife and his physicians. Read the narrative about how Ed was finally diagnosed, what happened next, and where he is now.

This 10-year study is the first large, population-based assessment of spasticity treatment in MS. It reveals that younger, newly diagnosed people are prescribed baclofen more their older peers. This is the first study to show high rates of baclofen discontinuation among all patients with MS, with more than 50% of patients discontinued treatment within 6 months.

The authors in this paper wanted to determine if, on the basis of basic clinical criteria, the stiff limb syndrome can be distinguished from the stiff man syndrome and progressive encephalomyelitis with rigidity, and whether this distinction has any bearing on the condition’s origin, course of treatment, or prognosis.

Relapsing MS treatment remains difficult, and new therapeutic targets have been investigated. S1P, a bioactive lysophospholipid signaling molecule present in several organs, including the central nervous system, is one such target. S1P plays a role in a variety of physiologic and pathophysiologic processes. S1P levels have been linked to disease progression in the brain parenchyma and cerebrospinal fluid of MS patients. There are 5 recognized S1PR subtypes, and depending on the receptor being targeted, their expression patterns and outcomes change. S1PRMs are a more recent class of RMS treatments, and the FDA has currently approved 4 of these treatments: fingolimod, siponimod, ozanimod, and ponesimod.